Rocket Pharmaceuticals (NASDAQ:RCKT) Given New $54.00 Price Target at Chardan Capital
Rocket Pharmaceuticals (NASDAQ:RCKT – Free Report) had its target price decreased by Chardan Capital from $62.00 to $54.00 in a research report report published on Friday morning,Benzinga reports. Chardan Capital currently has a buy rating on the biotechnology company’s stock. Other research analysts have also issued reports about the stock. Cantor Fitzgerald reissued an “overweight” […]
Rocket Pharmaceuticals (NASDAQ:RCKT – Free Report) had its target price decreased by Chardan Capital from $62.00 to $54.00 in a research report report published on Friday morning,Benzinga reports. Chardan Capital currently has a buy rating on the biotechnology company’s stock. Other research analysts have also issued reports about the stock. Cantor Fitzgerald reissued an “overweight” […]
